| Literature DB >> 33845942 |
Sabina Tahirovic1, Arthur Liesz2,3, Alessio Vittorio Colombo1, Rebecca Katie Sadler2, Gemma Llovera2, Vikramjeet Singh2, Stefan Roth2, Steffanie Heindl2, Laura Sebastian Monasor1, Aswin Verhoeven4, Finn Peters1, Samira Parhizkar5, Frits Kamp5, Mercedes Gomez de Aguero6, Andrew J MacPherson6, Edith Winkler1,5, Jochen Herms1,3,7, Corinne Benakis2, Martin Dichgans2,3, Harald Steiner1,5, Martin Giera4, Christian Haass1,5,3.
Abstract
Previous studies have identified a crucial role of the gut microbiome in modifying Alzheimer's disease (AD) progression. However, the mechanisms of microbiome-brain interaction in AD were so far unknown. Here, we identify microbiota-derived short chain fatty acids (SCFA) as microbial metabolites which promote Aβ deposition. Germ-free (GF) AD mice exhibit a substantially reduced Aβ plaque load and markedly reduced SCFA plasma concentrations; conversely, SCFA supplementation to GF AD mice increased the Aβ plaque load to levels of conventionally colonized (specific pathogen-free [SPF]) animals and SCFA supplementation to SPF mice even further exacerbated plaque load. This was accompanied by the pronounced alterations in microglial transcriptomic profile, including upregulation of ApoE. Despite increased microglial recruitment to Aβ plaques upon SCFA supplementation, microglia contained less intracellular Aβ. Taken together, our results demonstrate that microbiota-derived SCFA are critical mediators along the gut-brain axis which promote Aβ deposition likely via modulation of the microglial phenotype.Entities:
Keywords: alzheimer's disease; amyloid; immunology; inflammation; metabolites; microbiome; microglia; mouse; neuroinflammation; neuroscience
Year: 2021 PMID: 33845942 DOI: 10.7554/eLife.59826
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.140